ArticleBMC cardiovascular disorders2026
Serum Human epididymal protein 4 as a predictor of adverse events in acute ischemic stroke patients receiving antiplatelet therapy.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute kidney injury (AKI) frequently develops in certain patients with acute ischemic stroke (AIS) and often indicates a poor prognosis. However, the relationship between serum human epididymal protein 4 (HE4), a newly recognized biomarker of renal injury, and adverse outcomes in AIS patients remains unclear.
aimThis study aimed to investigate the prognostic value of admission serum HE4 levels for predicting unfavorable outcomes in AIS patients undergoing antiplatelet therapy.
methodsWe conducted a cohort study involving 144 consecutive adult patients admitted for AIS who received antiplatelet treatment. Blood samples were collected after admission to measure serum HE4 concentrations.
resultsSerum HE4 levels were markedly elevated in AIS patients on antiplatelet therapy compared with healthy controls (116.4 ± 24.8 pmol/L vs. 25.3 ± 9.8 pmol/L). Kaplan-Meier analysis revealed that higher HE4 levels were associated with an increased incidence of cardiovascular events and/or recurrent stroke. Multivariate Cox regression analysis indicated that elevated HE4 concentrations independently predicted a higher risk of cardiovascular events (HR = 3.02; 95% CI: 1.51-6.29; P = 0.01) and stroke recurrence (HR = 3.81; 95% CI: 1.64-6.63; P < 0.01).
conclusionsElevated serum HE4 levels are significantly associated with a heightened risk of cardiovascular events and recurrent stroke in AIS patients receiving antiplatelet therapy, suggesting that HE4 may serve as a potential biomarker for predicting adverse outcomes in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.